Especifique uma ação ou criptomoeda na barra de pesquisa para obter um resumo
Astellas Pharma Inc
YPHAstellas Pharma Inc. manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also offers Evrenzo, a treatment for anemia associated with chronic kidney disease; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf and Advagraf/Graceptor/ASTAGRAF XL immunosuppressants. Th company has a research collaboration with Vivtex Corporation to evaluate Vivtex's GI-ORIS screening and formulation platform technology to support the development of novel and oral versions of a therapeutic candidate provided by Astellas; and a partnership agreement with Roche Diabetes Care Japan Co., Ltd. to develop and commercialize integrated diabetes self-management solution. The company was founded in 1923 and is headquartered in Tokyo, Japan. Address: 2-5-1, Nihonbashi-Honcho, Tokyo, Japan, 103-8411
Analytics
Preço Alvo de Wall Street
–Rácio P/E
128.625Rendimento de dividendos
4.41 %Ano atual
Ano passado
Trimestre Atual
Ultimo quarto
Ano atual
Ano passado
Trimestre Atual
Ultimo quarto
Figuras chave YPH
Análise de Dividendos YPH
Crescimento de dividendos em 5 anos
76 %Crescimento contínuo
10 anosTaxa de pagamento em média de 5 anos
66 %Histórico de Dividendos YPH
Avaliação de ações YPH
Relatório YPH
Acompanhe as principais métricas de cada ação em um só lugar, sem complicações
Inscreva-se no premiumResultados | 2019 | Dinâmica |